Brainstorm Cell Therapeutics Files 8-K
Ticker: BCLI · Form: 8-K · Filed: May 15, 2025 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | May 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-condition, operations
TL;DR
Brainstorm Cell Therapeutics filed an 8-K on May 15, 2025, regarding financial condition and operations.
AI Summary
On May 15, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.
Why It Matters
This 8-K filing indicates that Brainstorm Cell Therapeutics Inc. is providing updates on its financial condition and operations to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain specific negative or positive news that would immediately impact risk.
Key Players & Entities
- Brainstorm Cell Therapeutics Inc. (company) — Registrant
- May 15, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Brainstorm Cell Therapeutics Inc.?
The 8-K filing is for reporting the company's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 15, 2025.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Brainstorm Cell Therapeutics Inc.'s state of incorporation?
Brainstorm Cell Therapeutics Inc. is incorporated in Delaware.
What is the Commission File Number for Brainstorm Cell Therapeutics Inc.?
The Commission File Number for Brainstorm Cell Therapeutics Inc. is 001-36641.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding BRAINSTORM CELL THERAPEUTICS INC. (BCLI).